COMPARE · Reviewed August 3, 2026
PGNY vs UNH
Verdict: Side-by-side breakdown using the Bull Rankings model. PGNY scored 63.3, UNH scored 61.8 — PGNY leads.
Compare another set
PGNY
Progyny, Inc.
63.3
$31.55 · $2.5B
fundamentals as of
Score gap
1.5
PGNY leads
UNH
UnitedHealth Group Incorporated
61.8
$410.32 · $372.6B
fundamentals as of
The model, pillar by pillar (0–100 each)
PGNY
stronger →← stronger
UNH
82
Qualityreturns · margins · balance sheet
59
72
Growthrevenue & earnings expansion
87
43
Valuevaluation vs sector peers
46
UNH is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
PGNY
UNH
$184mC
FCF
$19.7bA-
+6.6%C+
Rev
+11.8%B
0.06A-
D/E
0.69C+
41.0xC
P/E
30.9xB
3.94D
PEG
1.28B
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
PGNY
UNH
20% below
Price vs fair valuelower is cheaper
27% below
~1%/yr
Growth the price implies10-yr FCF · lower = less priced in
~1%/yr
+15%
1-yr DCF upside
+20%
+25%
5-yr DCF upside
+37%
+40%
10-yr DCF upside
+68%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
PGNY
Why this score
- Buying back stock
- Durable high returns
UNH
Why this score
- Raising its dividend
The companies
PGNYProgyny, Inc.
Why now
Healthcare Plans · market cap $2.5b. 5% off the 52-week high of $33.06. 11 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $34.00 (implying +8% upside).
Moat
ROE 15% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk
Trailing P/E 41x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
UNHUnitedHealth Group Incorporated
Why now
Healthcare Plans · market cap $372.6b. 11% off the 52-week high of $461.62. Revenue growing +12%, comfortably above the S&P median. 26 sell-side analysts rate this a Buy with a mean 1-yr target of $475.23 (implying +16% upside).
Moat
ROE 14% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 139% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. $372.6b market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk
Trailing P/E 31x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Net margin 3.1% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.